Trials Sponsors Conditions Drugs Pricing

Conditions

Keywords

muscle-invasive bladder cancerPET/CT18F-FDG PETneoadjuvant chemotherapydiagnostic accuracyradiomicsartificial intelligence

Outcome Measures

Primary Outcomes (2)

Baseline Diagnostic Accuracy of [18F]FDG PET/CT in MIBC
Assessment of \[18F\]FDG PET/CT for initial staging of newly diagnosed muscle-invasive bladder cancer, compared with thoraco-abdomino-pelvic contrast-enhanced CT (gold standard) to determine diagnostic accuracy in defining disease extent.
At baseline, prior to initiation of neoadjuvant therapy (each cycle has a duration of 21 days)
Interim [18F]FDG PET/CT Prediction of Pathological Response
Evaluation of the ability of interim \[18F\]FDG PET/CT to predict pathological response to neoadjuvant treatment, assessing its potential role in guiding therapeutic decision-making.
After 2 cycles of neoadjuvant therapy, prior to surgery (each cycle has a duration of 21 days)

Study Arms (1)

adults with high-grade MIBC

adults aged 18 years or older with a histologically confirmed diagnosis of high-grade MIBC

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

adults aged 18 years or older with a histologically confirmed diagnosis of high-grade MIBC

You may qualify if:

Adults aged 18 years or older Previously known oncological disease Histologically confirmed diagnosis of high-grade MIBC Non-muscle-invasive, or low-grade bladder cancer

Sponsors & Collaborators

University Hospital of Ferrara
Otherlead

Study Sites (1)

Azienda Ospedaliero-Universitaria di Ferrara

Ferrara, 44124, Italy

RECRUITING

Luca Urso, MDCONTACT+390532236906 luca.urso@unife.it

Francesca CanellaCONTACTfrancesca.canella@ausl.fe.it

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

February 23, 2026

First Posted

August 6, 2026

Study Start

April 16, 2024

Actual (reported)

Primary Completion

December 2026

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Diagnostic Accuracy of 18F-FDG PET/CT in Muscle-invasive Bladder Cancer

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Study Arms (1)

adults with high-grade MIBC

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Study Arms (1)

adults with high-grade MIBC

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations